

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Simcere Pharmaceutical Group Limited

先聲藥業集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock code: 2096)

VOLUNTARY ANNOUNCEMENT

RECEIPT OF RECENT MILESTONE PAYMENT UNDER SIM0500 OPTION TO LICENSE AGREEMENT WITH ABBVIE

This announcement is made by Simcere Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform shareholders and potential investors of the Company regarding the latest business development of the Group.

The Company announced on January 13, 2025 that a subsidiary of the Group had entered into an option to license agreement (the “**Agreement**”) with a subsidiary of AbbVie Inc. (“**AbbVie**”) in respect of the investigational new drug candidate SIM0500. Pursuant to the terms of the Agreement, the Group is entitled to receive an upfront payment from AbbVie, and is eligible to receive option fees and milestone payments of up to US\$1.055 billion, and the parties have agreed on tiered royalty arrangements in respect of the net sales.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that, following the receipt of the upfront payment under the Agreement, the Group has recently further received a payment of US\$40 million from AbbVie (the “**Payment**”). The payment showcases the progress of the collaboration between the Group and AbbVie to advance the clinical development of SIM0500.

ABOUT SIM0500

SIM0500 is a humanized trispecific antibody that targets GPRC5D, BCMA, and CD3, developed independently by the Group using T-cell engager poly-specific antibody technology platform. This molecule features a low affinity/high target-activating CD3 engaging arm and binding sites for the two tumor antigens: G-Protein-coupled receptor class 5 member D (GPRC5D) and B-cell maturation antigen (BCMA). SIM0500 has shown strong T cell cytotoxicity against multiple myeloma (MM) cells by leveraging a combination of various antitumor effects.

ABOUT THE GROUP

The Company is an innovation and R&D-driven pharmaceutical company and the Group has established a “State Key Laboratory of Neurology and Oncology Drug Development”. The Group focuses on the therapeutic areas of neuroscience, anti-oncology, autoimmune and anti-infection, with forward-looking layout of disease areas that may have significant clinical needs in the future, aiming to achieve the mission of “for patients, for life”. Driven by its in-house R&D efforts and synergistic innovation, the Company has established strategic cooperation partnerships with many innovative companies and research institutes.

By order of the Board
Sincere Pharmaceutical Group Limited
Mr. Ren Jinsheng
Chairman and Chief Executive Officer

Hong Kong, February 3, 2026

As at the date of this announcement, the Board comprises Mr. REN Jinsheng as the Chairman and executive Director; Mr. TANG Renhong, Mr. WAN Yushan and Ms. WANG Xi as the executive Directors; Mr. SONG Ruilin, Mr. WANG Jianguo, Mr. WANG Xinhua and Mr. SUNG Ka Woon as the independent non-executive Directors.